REMEDi4ALL - Standard Operating Procedure - Two drug combination test: detection of synergetic anti-proliferative effect in cancer cell lines
This SOP describes the application of the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) for detection of the synergetic anti-proliferative effect in pancreatic cancer cell lines based on small molecule treatment. It describes the procedure of compound- and cell-preparation to detect and analyse the anti-proliferative synergetic effect of compounds. IMPORTANT: for each new cell line and each new tested compound pair the cell number/well and the specific CC50s of tested compounds should be evaluated before the application of this SOP. See also Standard Operating Procedure SOP-R4A-1.1 “Drugs combination screening”
Institutions
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2025-10-08
- DOI
- https://doi.org/10.5281/zenodo.17293604
- Primary Topic
- bioluminescence and chemiluminescence research
- Type
- article
- Field-Weighted Citation Impact
- 0.00